The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Is mda-7/IL-24 a “Magic Bullet” for Cancer?
Abstract
The “holy grail” of cancer therapy is to identify and exploit genetic elements and signal transduction pathways capable of selectively destroying tumor cells without eliciting harmful effects in normal cells or tissues. To achieve this objective, subtraction hybridization was combined with a “differentiation therapy” model of cancer in which human melanoma cells were induced to revert to a more “normal” state, growth arrest irreversibly, and terminally differentiate by treatment with fibroblast IFN and mezerein. This strategy permitted the cloning of a variety of genes involved in regulating important physiologic processes, including cell cycle, response to cytokines and viruses, tumorigenesis and metastasis, cancer growth control, apoptosis, and senescence. A specific gene, melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), displaying cancer-specific apoptosis-inducing properties isolated using this scheme has now come into the limelight as a new gene therapy for divergent cancers. Although the mechanism of cancer cell selectivity of mda-7/IL-24 remains to be delineated, numerous attributes enable this gene as an effective therapy for cancer, including an ability to discriminate between normal and cancer cells, induce apoptosis in diverse tumor cells, promote “bystander” antitumor effects, inhibit tumor growth and angiogenesis in animal models, synergize with radiation, and modulate immune responses. These unique features combined with successful transition into the clinic instill confidence that mda-7/IL-24, as a single or more likely as part of a combinatorial approach, may provide profound therapeutic benefit for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dumoutier, L., Leemans, C., Lejeune, D., Kotenko, S. V., & Renauld, J.-C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3545 · Cited by 405
Molecular markers of early pancreatic cancer
Goggins, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.711 · Cited by 214
Cited by
GADD45 Proteins: Central Players in Tumorigenesis
E. Tamura, R., F. de Vasconcellos, J., Sarkar, D., A. Libermann, T., B. Fisher, P., & F. Zerbini, L. (2012) · Current Molecular Medicine · doi:10.2174/156652412800619978 · Cited by 340
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
Self-citationTargeting the Bcl-2 family for cancer therapy
Thomas, S., Quinn, B. A., Das, S. K., Dash, R., Emdad, L., Dasgupta, S., Wang, X.-Y., Dent, P., Reed, J. C., Pellecchia, M., et al. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.733001 · Cited by 277
Self-citationCytokine expression and signaling in drug-induced cellular senescence
Novakova, Z., Hubackova, S., Kosar, M., Janderova-Rossmeislova, L., Dobrovolna, J., Vasicova, P., Vancurova, M., Horejsi, Z., Hozak, P., Bartek, J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.318 · Cited by 127
PKR in Innate Immunity, Cancer, and Viral Oncolysis
Balachandran, S., & Barber, G. N. (2007) · Cancer Genomics and Proteomics · doi:10.1007/978-1-59745-335-6_18 · Cited by 65
Metadata
- Authors
- Fisher, P. B.
- Venue
- Cancer Research
- Published
- 2005-11-15
- Volume
- 65
- Issue
- 22
- Pages
- 10128-10138
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2022315435
- Cited by
- 201
- References
- 2
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is mda-7/IL-24 a “Magic Bullet” for Cancer? https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3127
- The paper
- Fisher, P. B. (2005). Is mda-7/IL-24 a “Magic Bullet” for Cancer? Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.